Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP5541 + Prednisolone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP5541 | PRL02|PRL 02|Abiraterone Decanoate Depot|PRL-02 | Hormone - Anti-androgens 57 | ASP5541 (PRL-02) is a long-acting formulation of abiraterone, which may lead to suppression of testosterone levels and decreased tumor cell proliferation (J Clin Oncol 39, 2021 (suppl 15; abstr TPS5090), NCI Drug Dictionary). | |
| Prednisolone | Omnipred | Deltahydrocortisone |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07005154 | Phase II | ASP5541 ASP5541 + Prednisolone Abiraterone + Prednisolone Abiraterone + Prednisone ASP5541 + Prednisone | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Recruiting | USA | 2 |